ADC Therapeutics SA - Common Shares (ADCT) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / Common Shares
Symbol
ADCT on NYSE
Shares outstanding
124,058,172
Price per share
$3.53
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
68,158,412
Total reported value
$272,625,712
% of total 13F portfolios
0%
Share change
-2,717,131
Value change
-$9,526,921
Number of holders
105
Price from insider filings
$3.53
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ADC Therapeutics SA - Common Shares (ADCT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 14% $41,986,839 15,666,731 Redmile Group, LLC 30 Jun 2025
HPWH TH AG 9.6% $14,291,858 9,788,944 Dr. Hans-Peter Wild 15 May 2025
Point72 Asset Management, L.P. 7% $21,693,047 7,831,425 Point72 Asset Management, L.P. 16 Jun 2025
Prosight Management, LP 5.8% $28,781,496 7,195,374 Prosight Management, LP 30 Sep 2025
BlackRock, Inc. 5% -4% $7,173,203 -$144,108 4,913,153 -2% BlackRock, Inc. 31 Mar 2025
Oaktree Capital Group Holdings GP, LLC 4.1% $18,693,764 4,673,441 Oaktree Fund Administration, LLC 30 Sep 2025
ORBIMED ADVISORS LLC 3.6% $5,019,207 3,437,813 ORBIMED CAPITAL LLC 31 Dec 2024

As of 30 Sep 2025, 105 institutional investors reported holding 68,158,412 shares of ADC Therapeutics SA - Common Shares (ADCT). This represents 55% of the company’s total 124,058,172 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ADC Therapeutics SA - Common Shares (ADCT) together control 51% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Redmile Group, LLC 13% 15,666,731 0% 6.1% $62,666,924
Point72 Asset Management, L.P. 6.6% 8,135,651 +4.8% 0.07% $32,542,604
Prosight Management, LP 6% 7,472,303 -29% 7.2% $29,889,212
ORBIMED ADVISORS LLC 4.8% 5,907,351 0% 0.57% $23,629,404
BlackRock, Inc. 3.6% 4,511,699 -0.21% 0% $18,046,796
MORGAN STANLEY 3% 3,669,067 +20% 0% $14,676,268
Nantahala Capital Management, LLC 1.8% 2,266,289 0% 0.56% $9,065,156
GOLDMAN SACHS GROUP INC 1.3% 1,594,434 +3.4% 0% $6,377,736
TCG Crossover Management, LLC 1.1% 1,390,175 0.27% $5,560,700
BANK OF AMERICA CORP /DE/ 1.1% 1,361,290 -38% 0% $5,445,160
Lynx1 Capital Management LP 1.1% 1,325,848 1.1% $5,303,392
STATE STREET CORP 1% 1,295,941 +5% 0% $5,183,764
PLATINUM INVESTMENT MANAGEMENT LTD 0.93% 1,156,721 -17% 0.3% $4,626,884
GEODE CAPITAL MANAGEMENT, LLC 0.7% 862,934 +0.48% 0% $3,451,736
CITADEL ADVISORS LLC 0.66% 820,715 +2729% 0% $3,282,860
Blue Owl Capital Holdings LP 0.59% 733,568 0% 0.91% $2,934,272
MILLENNIUM MANAGEMENT LLC 0.57% 701,619 +83% 0% $2,806,476
BNP PARIBAS FINANCIAL MARKETS 0.55% 688,471 0% 0% $2,753,884
Vantage Consulting Group Inc 0.55% 682,998 0% 24% $2,731,992
Opaleye Management Inc. 0.55% 682,529 0.39% $2,730,116
VANGUARD GROUP INC 0.48% 593,954 +6% 0% $2,375,816
PANAGORA ASSET MANAGEMENT INC 0.44% 544,261 +101% 0.01% $2,177,044
JANE STREET GROUP, LLC 0.39% 487,868 0% $1,951,472
NORTHERN TRUST CORP 0.34% 417,567 -2.2% 0% $1,670,268
JPMORGAN CHASE & CO 0.27% 330,597 +865% 0% $1,322,388

Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 56,103 $198,054 +$100,467 $3.53 5
2025 Q3 68,158,412 $272,625,712 -$9,526,921 $4.00 105
2025 Q2 67,952,003 $182,114,158 +$35,606,077 $2.68 84
2025 Q1 54,846,167 $77,332,587 -$2,528,133 $1.41 82
2024 Q4 56,494,277 $112,422,732 -$3,041,138 $1.99 82
2024 Q3 54,883,537 $172,881,709 +$3,394,419 $3.15 76
2024 Q2 51,801,951 $163,693,841 +$51,364,315 $3.16 73
2024 Q1 34,683,534 $155,728,721 +$7,168,355 $4.49 36
2023 Q4 33,953,461 $56,361,695 -$3,915,509 $1.66 36
2023 Q3 39,458,503 $35,390,528 -$10,272,333 $0.90 40
2023 Q2 45,357,348 $97,515,460 -$1,939,928 $2.15 55
2023 Q1 46,611,135 $90,890,151 +$6,156,453 $1.95 57
2022 Q4 38,834,584 $149,117,927 +$3,712,534 $3.84 59
2022 Q3 36,621,247 $176,523,672 +$9,038,590 $4.82 60
2022 Q2 34,475,113 $274,062,429 +$4,571,679 $7.95 52
2022 Q1 34,123,674 $501,279,862 +$2,970,760 $14.69 44
2021 Q4 33,799,357 $682,750,000 +$19,180,842 $20.20 50
2021 Q3 32,792,604 $890,647,136 -$45,594,727 $27.16 51
2021 Q2 33,533,099 $816,251,800 +$17,173,667 $24.35 53
2021 Q1 32,826,058 $801,283,858 +$19,636,706 $24.41 55
2020 Q4 32,141,073 $1,028,835,000 +$31,200,598 $32.01 51
2020 Q3 28,226,306 $921,776,783 +$216,837,760 $32.99 51
2020 Q2 21,557,623 $1,000,339,109 +$1,000,339,111 $46.81 41